A Phase 3 Randomized Double-Blind Placebo-Controlled Event-Driven Study to Investigate the Effect of Retatrutide on the Reduction of Major Adverse Cardiovascular Events (MACE) and/or Adverse Kidney Outcomes in Participants with Body Mass...